An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Loading...
Embargo End Date
Authors
Patel, R
Barker, HE
Kyula, J
McLaughlin, M
Dillon, MT
Schick, U
Hafsi, H
Thompson, A
Khoo, V
Harrington, K
Zaidi, S
Barker, HE
Kyula, J
McLaughlin, M
Dillon, MT
Schick, U
Hafsi, H
Thompson, A
Khoo, V
Harrington, K
Zaidi, S
Document Type
Journal Article
Date
2017-03-01
Date Accepted
Abstract
PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities. MATERIALS AND METHODS: We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models. RESULTS: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis. CONCLUSIONS: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.
Citation
RADIOTHERAPY AND ONCOLOGY, 2017, 122 (3), pp. 470 - 475
Source Title
Publisher
ELSEVIER IRELAND LTD
ISSN
0167-8140
eISSN
1879-0887
Research Team
Targeted Therapy